Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 2/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
| ▸ | CCNH | P51946 | 1/20 | 0.31 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29325879 | 0.81 | IRAK4 (0.35) | CCNT1CDK9 | |
| SCHEMBL29325872 | 0.81 | IRAK4 (0.35) | CCNT1CDK9 | |
| SCHEMBL29325964 | 0.79 | MAPK8 (0.39) | CCNT1CDK2CDK9CDK7 | |
| SCHEMBL29155917 | 0.79 | MAPK8 (0.39) | CCNT1CDK2CDK9CDK7 | |
| SCHEMBL29326237 | 0.79 | MAPK8 (0.39) | CCNT1CDK2CDK9CDK7 | |
| SCHEMBL29326234 | 0.79 | MAPK8 (0.39) | CCNT1CDK2CDK9CDK7 | |
| SCHEMBL29325972 | 0.79 | MAPK8 (0.39) | CCNT1CDK2CDK9CDK7 | |
| SCHEMBL29155922 | 0.79 | MAPK8 (0.39) | CCNT1CDK2CDK9CDK7 | |
| SCHEMBL30684778 | 0.79 | MAPK8 (0.39) | CCNT1CDK2CDK9CDK7 | |
| SCHEMBL29325869 | 0.78 | MAPK10 (0.36) | CCNE1CDK2CDK9CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630417-A1 | NOVEL COMPOUNDS AS MODULATORS OF NLRP3 INHIBITION | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121086-A1 | NOVEL COMPOUNDS AS MODULATORS OF NLRP3 INHIBITION | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | disclosed |